back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2021-07-06 19:30 Tx date 2021-06-29 |
$ASP
Acerus Pharmaceuticals Corporation |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$185,469
+3,872,013 vol $0.0479 each |
9,494,722 | |
| Filed 2020-11-27 13:18 Tx date 2020-11-26 |
$ASP
Acerus Pharmaceuticals Corporation |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$614.63
+24,585 vol $0.025 each |
71,785 | |
| Filed 2020-04-02 18:07 Tx date 2020-03-30 |
$ASP
Acerus Pharmaceuticals Corporation |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$187,490
+4,148,017 vol $0.0452 each |
5,622,709 | |
| Filed 2019-08-09 15:49 Tx date 2019-08-08 |
$ASP
Acerus Pharmaceuticals Corporation |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+249,420 vol |
1,474,692 | |
| Filed 2018-12-07 Tx date 2018-12-07 |
$ASP
Acerus Pharmaceuticals Corporation |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,917
+14,200 vol $0.135 each |
47,200 | |
| Filed 2018-03-26 Tx date 2018-03-23 |
$ASP
Acerus Pharmaceuticals Corporation |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+225,272 vol |
1,225,272 | |
| Filed 2017-11-15 Tx date 2016-07-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2017-11-15 Tx date 2017-11-15 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,950
+33,000 vol $0.15 each |
33,000 | |
| Filed 2017-11-13 Tx date 2017-11-09 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$60,000
+500,000 vol $0.12 each |
1,000,000 | |
| Filed 2017-03-13 Tx date 2017-03-10 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
500,000 | |
| Filed 2016-08-12 Tx date 2016-08-11 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+300,000 vol |
300,000 | |
| Filed 2016-08-12 Tx date 2016-07-04 |
$ASP
Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation) |
Savard, Philippe Perron
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|